About MacroGenics
MacroGenics is a company based in Rockville (United States) founded in 2000. It operates as a Professional Services. MacroGenics has raised $126.02 million across 13 funding rounds from investors including Lilly, ARE and NIH. The company has 341 employees as of December 31, 2024. MacroGenics has completed 1 acquisition, including Raven Biotechnologies. MacroGenics offers products and services including Lorigerlimab, MGC026, MGC028, and MGD024. MacroGenics operates in a competitive market with competitors including argenx, Alexion, Zai Lab, Kodiak Sciences and BigHat, among others.
- Headquarter Rockville, United States
- Employees 341 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Macrogenics, Inc.
-
Annual Revenue
$149.96 M (USD)155.26as on Dec 31, 2024
-
Net Profit
-$66.97 M (USD)-639.3as on Dec 31, 2024
-
EBITDA
-$103.04 M (USD)35.03as on Dec 31, 2024
-
Total Equity Funding
$126.02 M (USD)
in 13 rounds
-
Latest Funding Round
Not available
-
Investors
Lilly
& 22 more
-
Employee Count
341
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MacroGenics
MacroGenics is a publicly listed company on the NASDAQ with ticker symbol MGNX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MacroGenics
MacroGenics offers a comprehensive portfolio of products and services, including Lorigerlimab, MGC026, MGC028, and MGD024.
Innovative antibody therapy targeting PD-1 and CTLA-4 proteins.
Antibody-drug conjugate targeting B7-H3 for cancer treatment.
Antibody-drug conjugate targeting ADAM9 for cancer therapy.
Bispecific antibody targeting CD123 and CD3 molecules.
People of MacroGenics
Unlock access to complete
Unlock access to complete
Leadership Team
38 people
Software Development Team
17 people
Operations Team
12 people
Data Analysis and Operations Team
11 people
Product Management Team
8 people
Senior Team
4 people
Finance and Accounting
3 people
Associate Team
3 people
Unlock access to complete
Funding Insights of MacroGenics
MacroGenics has successfully raised a total of $126.02M across 13 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MacroGenics
MacroGenics has secured backing from 23 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, ARE and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Arcus Ventures is focused on investing in oncology companies.
|
Locked | Locked | Locked |
Investor details for MacroGenics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MacroGenics
MacroGenics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Raven Biotechnologies.
Investment portfolio details for MacroGenics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Monoclonal antibodies targeting cell surfaces for cancer therapies are developed.
|
Locked | Locked | 1998 | Locked |
Complete acquisition details for MacroGenics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MacroGenics
Detailed financials for MacroGenics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Macrogenics Comparisons
Peer comparison for MacroGenics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MacroGenics
MacroGenics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as argenx, Alexion, Zai Lab, Kodiak Sciences and BigHat, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| Locked | Locked | Locked |
Antibody-based therapies for cancers and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for retinal diseases are developed by the company.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
Detailed competitors of MacroGenics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Macrogenics
Complete news archive for MacroGenics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MacroGenics
MacroGenics was founded in 2000 and raised its 1st funding round 1 year after it was founded.
MacroGenics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
MacroGenics is a funded company, having raised a total of $126.02M across 13 funding rounds to date.
As of Dec 31, 2024, the latest employee count at MacroGenics is 341.
Annual revenue of MacroGenics is $149.96M as on Dec 31, 2024.
MacroGenics, Inc. is engaged in the development and commercialization of innovative monoclonal antibody-based therapeutics for cancer treatment. The company operates within the biopharmaceutical sector, focusing on unmet medical needs through a broad pipeline of investigational product candidates. Solutions are developed using advanced antibody-based technologies and fully-integrated development capabilities, including GMP manufacturing. Efforts are directed towards creating breakthrough biologics aimed at transforming patient outcomes in oncology.
MacroGenics's top competitors include argenx, Zai Lab and Kodiak Sciences.
MacroGenics offers Lorigerlimab, MGC026, MGC028, and MGD024.
Yes, MacroGenics is publicly traded on NASDAQ under the ticker symbol MGNX.
MacroGenics has made 1 acquisition, including Raven Biotechnologies.
The ticker symbol of MacroGenics is MGNX on NASDAQ.